[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Precision Dynamics Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":74},{"warningLetters":4,"total":73},[5,31,50],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1097,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:00:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-09T05:00:00Z\">12\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphillips-precision-inc-697119-12092024\">Phillips Precision, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeanne M. Phillips\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Phillips Precision, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7 Paul Kohner Pl\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elmwood Park\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07407\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 697119\u003C\u002Fp>\u003Cp>December 9, 2024\u003C\u002Fp>\u003Cp>Dear Ms. Jeanne M. Phillips:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Elmwood Park, NJ on April 22, 2024 through July 17, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures orthopedic implants and instruments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Ms. Shalyn Creighton, Quality Assurance and Regulatory Compliance Manager, dated August 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you either failed to adequately implement or define and document requirements for your “Master Validation Plan Process and Software Validation” procedure (SOP-34; Rev. M and O; Effective: 6\u002F13\u002F14 and 5\u002F9\u002F19) which governed process validations for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> processes. For example:\u003C\u002Fp>\u003Cp>A. Cleaning validations conducted for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” used to \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean orthopedic implants and instruments, for which your firm functions as the final cleaner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> top customers, do not provide adequate assurance that the process consistently produces product that meets specifications. For example:\u003C\u002Fp>\u003Cp>1. You failed to adequately implement sections 5.3.7 and 5.3.9.3 of your process validation procedure (SOP-34; Rev. M) which required you to challenge your cleaning process under the worst-case product and process conditions during the operational qualification (OQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” conducted under “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Operational Qualification (OQ) Protocol” (OQ_920-001; Rev. B; Approved 2\u002F5\u002F15), which includes the report. For example:\u003C\u002Fp>\u003Cp>i. Although your performance qualification (PQ) protocol required cytotoxicity, endotoxin, and particulate testing for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to demonstrate that cleanliness requirements were consistently met, you failed to conduct such testing during OQ which is defined in your procedure as “***documented verification that equipment performs in accordance with manufacturer’s specifications and process operating at [sic] the extremes of the equipment or process operating capabilities***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately challenge the cleaning process under worst-case process parameters and product based on types and\u002For geometries, surface finishes, and processes conducted during OQ. For example, you did not challenge \u003Cstrong>(b)(4)\u003C\u002Fstrong> as all loads were run at \u003Cstrong>(b)(4)\u003C\u002Fstrong>; system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality above \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002F cm; clean time below \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes; and load weight above \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds. You also failed to define the worst-case setting for degassing time in the OQ protocol which your firm’s management stated is under \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes as well as document the degassing time during OQ.\u003C\u002Fp>\u003Cp>In addition, you executed work orders during OQ without the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process, which your firm’s management identified during the inspection as a process that challenges your firm’s surface finishes and equipment process capabilities in \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> work (WO #: 99343, 99284, 99336, and 98026-1) which were provided as worst case products.\u003C\u002Fp>\u003Cp>Furthermore, our investigator observed adhesive tape on the proximal femur left plasma implant (PF-2000L-02M; WO 102275) in the finishing department on 4\u002F26\u002F24. However, your OQ did not include challenges associated with the removal of adhesives and your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) does not establish cleaning specifications associated with this process.\u003C\u002Fp>\u003Cp>iii. You failed to define or document the load configuration for work orders 65926 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 64205 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 63988 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 65917 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 65921 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>75 devices), and 65791 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices) in the OQ protocol and report in that your firm could not determine if devices were put in a single cleaning load or broken up into multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you failed to challenge different loading configurations that your firm’s management stated are used during routine production such as the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> which is allowed in section 5.2.4.2.6 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On 4\u002F26\u002F24, our investigator observed the tibia stylus assembly instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 101881) enclosed in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98151) placed on top of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, neither of which were evaluated during OQ.\u003C\u002Fp>\u003Cp>2. You failed to adequately implement section 5.3.9.4 of process validation procedure (SOP-34; Rev. M) which required “***documented evidence that a process system performs as intended and that it demonstrates the capability to consistently meet appropriate specifications***” for the performance qualification (PQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” conducted under “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report. For example:\u003C\u002Fp>\u003Cp>i. As specified in section 5.2.2 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), you are to ensure that the system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality of the rinse tank is below (≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm) during normal operation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner. However, you failed to conduct PQ under normal operating conditions for system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality in that only \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> runs were run at ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm while the remaining cycles were run at \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm. In addition, you failed to define the optimal setting for degassing time in the PQ protocol as well as document the degassing time during execution of your PQ.\u003C\u002Fp>\u003Cp>ii. You failed to utilize \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> which were sufficiently representative of manufactured devices. For example, WO # 99284 (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes surface finishes such as vibratory, deburring, and finishing and equipment processes such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, assembly, machine, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, these processes were not represented in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> utilized during your PQ and your firm did not document justification for the equivalency of those \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> through objective evidence.\u003C\u002Fp>\u003Cp>3. You failed to adequately implement section 5.1 of your process validation procedure (SOP-34; Rev. M) which requires a completed process failure modes and effects analysis (PFMEA) as a part of an approved validation plan and for which the definition under section 5.3.14 indicates that a PFMEA is used to “***assess quality risk levels to each step in a manufacturing process***” with a reference to your “Risk Management” procedure (SOP-35; Rev. K; Effective: 3\u002F9\u002F15) which outlines the criteria for severity scores on a scale of \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, per section 10.4 of the “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Validation Plan” (VP_920_001; Rev. D; Effective: 3\u002F31\u002F15) for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you utilized a PFMEA to assess quality risk levels that “***reflect[ed] the worst case process (for both clean and rinse) via processing***at maximum loading conditions (i.e. weight) for variable \u003Cstrong>(b)(4)\u003C\u002Fstrong> states @ \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>***.” However, you assigned a severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all but one of the failure modes for devices cleaned with your “Zenith” without determining if your firm was the final clean and if a severity score of 4 was appropriate. Your firm did not learn that it was the final clean for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your top customers until this information was requested during the inspection on 5\u002F2\u002F24. As of the close of the inspection, your firm had not evaluated the 8 other customers you have manufactured for since 2020 to determine if your firm is the final clean for them as well. For the 4 top customers for which your firm was the final cleaner, your firm manufactured and shipped \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4) \u003C\u002Fstrong>instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. You failed to adequately implement 5.3.8 of your process validation procedure (SOP-34; Rev. O) which requires “***documented evidence providing high degree of assurance that a process***will consistently perform as intended” in that:\u003C\u002Fp>\u003Cp>1. You have not conducted a process validation for additional post-production final cleaning processes listed in the “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), which allows for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to provide adequate assurance that the process will consistently produce product that meet specifications. For example, on 4\u002F22\u002F24 and 4\u002F26\u002F24, our investigator observed your operators using \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to wipe devices which had already been cleaned on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fp>\u003Cp>2. The “Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) only included devices composed of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> stainless steel and did not include devices composed of titanium (which your firm’s management stated are also treated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> during manufacturing) or documented justification for why validation of such devices was not necessary.\u003C\u002Fp>\u003Cp>C. You failed to adequately implement section 5.3.9.4 of your process validation procedure (SOP-34; Rev. M and O) which required “***documented evidence that a process system***demonstrates the capability to consistently meet appropriate specification***” and “***how\u002Fwhen samples will be taken, labeled, transported, and tested***” for the performance qualification (PQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. For example:\u003C\u002Fp>\u003Cp>1. Your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report, for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” did not utilize a sampling plan based on a valid statistical rationale for cytotoxicity, endotoxin, and particulate testing. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless otherwise specified, the number of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tested per lot for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively and the number of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units tested for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. An AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> units per lot would have required testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples per lot for each test.\u003C\u002Fp>\u003Cp>2. Your “Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) did not utilize a sampling plan based on a valid statistical rationale. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless otherwise specified, cytotoxicity testing was only conducted on \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lot and endotoxicity and particulate testing was conducted on \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lot. An AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> would have required a sufficient number of samples to be able to test a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples each for endotoxins, cytotoxicity, and particulates for a lot size between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to the OQ for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure and perform a revalidation which will challenge: the minimum and maximum critical process parameters with worst-case product and process \u003Cstrong>(b)(4)\u003C\u002Fstrong>; removal of any adhesives; load configurations; comingling; multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there was no confirmatory statement that you plan to conduct cytotoxicity, endotoxin, and particulate testing during OQ or rationale for why this would not be necessary and explanation provided for use of worst-case product and process \u003Cstrong>(b)(4)\u003C\u002Fstrong> instead of actual products during OQ.\u003C\u002Fp>\u003Cp>With regards to PQ for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you dispute that \u003Cstrong>(b)(4)\u003C\u002Fstrong> purity of the rinse tank was not conducted at nominal; however, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle was not done under normal operating conditions. You plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure and perform a revalidation to include notation of the degassing time and use of worst-case product \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there was no corrective action identified to run system \u003Cstrong>(b)(4)\u003C\u002Fstrong> purity under normal operating conditions (≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm) and define the optimal degassing time.\u003C\u002Fp>\u003Cp>With regards to the PFMEA for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you intend to review and update the existing PFMEA as needed; contact \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> customers you still do business with to determine whether your firm is the final clean and request their risk assessment; and do the same for any new customers in the future. However, there was no corrective action identified to proceduralized these actions. Furthermore, it is not clear whether you plan to update the respective severity scores for the process failure modes of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, for customer devices for which you are determined to be the final clean, in order to establish adequate quality risk levels.\u003C\u002Fp>\u003Cp>With regards to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to “amend” the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation to include devices composed of titanium. However, it is unclear what the difference is between an amendment and a revalidation.\u003C\u002Fp>\u003Cp>With regards to process validation for additional post-production cleaning processes, you state that the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and (medical grade) \u003Cstrong>(b)(4)\u003C\u002Fstrong> to wipe post-production and post-final-cleaning is done in accordance with customer requirements. However, no supporting evidence was provided and rationale for why post-production final cleaning processes would be needed if the final cleaning process is meant to assure that cleaning requirements can consistently be met.\u003C\u002Fp>\u003Cp>With regards to sampling, you plan to update the process validation procedure and ensure that the revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and amendment of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation will utilize a statistically valid sampling plan based on documented rationale.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21). For example:\u003C\u002Fp>\u003Cp>A. You failed to implement section 5.2.4.2.5 which states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” For example, on 4\u002F26\u002F24, our investigator observed comingling of the large \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 101395) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 99014) in the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> load.\u003C\u002Fp>\u003Cp>B. You failed to implement section 5.2.4.2.1 which states “Do not stack product.” For example, on 4\u002F26\u002F24, our investigator observed two instances where devices were stacked upon each other within a cleaning load: \u003Cstrong>(b)(4)\u003C\u002Fstrong> release instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98145) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98151), which appeared be stacked in 3 layers. In addition, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" manual specifically states that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to perform a revalidation on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to include challenges such as comingling and load configurations during OQ and review and update the PFMEA and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure, as applicable. However, you have not provided any timelines for completion of any of your corrective actions and there was no corrective action identified to address that your employees were not following procedures. Furthermore, it is not clear how a revalidation on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that challenges comingling will address the original purpose which was to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as noted in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fstrong> Specifically:\u003C\u002Fp>\u003Cp>A. You have not defined and documented procedures to monitor and control the following parameters for the validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) used to clean orthopedic implants and surgical instruments, for which your firm functions as the final cleaner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> top customers:\u003C\u002Fp>\u003Cp>1. \u003Cu>Weight of the Load \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu>:\u003C\u002Fu> There is no procedure to ensure that the load \u003Cstrong>(b)(4)\u003C\u002Fstrong> weight is below \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds, which was determined to be the limit during validation.\u003C\u002Fp>\u003Cp>2. \u003Cu>Batch-to-Batch Temperature of the Cleaning Solution (i.e., Detergent) in the Clean and Rinse Tanks:\u003C\u002Fu> There is no procedure to ensure that temperatures of the cleaning solution in the clean and rinse tanks between runs do not exceed the temperature limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉, which was determined to be the limit during validation.\u003C\u002Fp>\u003Cp>3. \u003Cu>Concentration of the Cleaning Solution (i.e., Detergent):\u003C\u002Fu> There is no procedure to ensure that the concentration of cleaning solution is monitored and controlled on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis (with the use of a titration kit or other suitable means) to ensure adequate cleaning, which was specified during validation to be established per manufacturer’s instructions.\u003C\u002Fp>\u003Cp>4. \u003Cu>Time for Degassing of Cleaning Solution (i.e., Detergent):\u003C\u002Fu> There is no procedure to ensure that your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, which operates at \u003Cstrong>(b)(4)\u003C\u002Fstrong>kHz, is degassed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes before use for effective cavitation, which was specified during validation to be established per manufacturer’s instructions.\u003C\u002Fp>\u003Cp>B. You failed to implement sections 5.2.1.2 and 5.2.2.4 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) which requires verification of the temperature of the cleaning solution (i.e., detergent) in the clean and rinse tanks to ensure it is in the validated range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ to \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ and documentation of the temperature on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning System Daily Temperature Log” (Form-03_01; Rev. F; Effective: 5\u002F25\u002F19) during startup of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Overall, review of the temperature log from January 2, 2023 and March 26, 2024 revealed that approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (\u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the loads run on your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” were performed at out of specification temperatures. For example, your employees operated your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner at temperatures lower than the minimum specified limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ on 2\u002F28\u002F23; 4\u002F6\u002F23; 4\u002F25\u002F23; 5\u002F19\u002F23; 5\u002F20\u002F23; 5\u002F22\u002F23; 5\u002F24\u002F23; and 7\u002F1\u002F23, implicating at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> orthopedic devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> surgical instruments).\u003C\u002Fp>\u003Cp>C. You have not established a procedure for the monitoring and control of temperature and time for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Section 6.2 of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” procedure (WI-920-005; Rev. F; Effective: 9\u002F6\u002F17) states that the “***\u003Cstrong>(b)(4)\u003C\u002Fstrong> is pre-heated***between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> F for a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to application.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to the inadequate monitoring and control of the above parameters, you plan to reevaluate monitoring and controls after revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”; update the frequency as needed; and revise the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to establish the applicable batch-to-batch temperature for the tanks.\u003C\u002Fp>\u003Cp>With regards to out of specification temperature recordings, you explain the temperatures would have increased as the morning went on such that only the first one or two runs of each day would have been affected; your employee may have misunderstood the process and either was not fully aware of the minimum temperature and\u002For what to do in the event the temperature was below the limit; and that because the minimum temperature proposed in the user manual is \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ and that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning action only begins to deteriorate when temperatures go above certain limits (typically \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉), the risk of impact to the parts cleaned on the specified days is low. However, there were temperatures noted above the validated temperature range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ on 8\u002F18\u002F23; 10\u002F10\u002F23; 1\u002F15\u002F24; 2\u002F1\u002F24; and 4\u002F1\u002F24. Additional temperatures below \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ were also noted on 8\u002F7\u002F23; 8\u002F12\u002F23; 8\u002F24\u002F23; and 11\u002F3\u002F23.\u003C\u002Fp>\u003Cp>You also plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to include an explanation of what to do in the event the temperature is below the minimum temperature; train applicable employees as well as to the nonconforming product procedure to identify nonconformances regarding parts themselves; and update the PFMEA to include the risks associated with parts processed outside of the specified temperature limits. However, there were no corrective actions identified to (1) address that your employees were not following procedures to ensure that the startup temperatures were within specified limits and (2) update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to specify how long employees should wait before measuring the temperature for verification before use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner.\u003C\u002Fp>\u003Cp>With regards to the inadequate monitoring and control of parameters for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to review the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation and establish the applicable monitoring and control and amend the \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure to these said controls.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A. You either failed to define and document requirements in your Corrective\u002F Preventive Action Process” procedure (SOP-29, Rev. F, Effective: 10\u002F19\u002F18) or adequately implement sections 5.3, 5.4, and 5.5 which require a “***comprehensive and thorough***” root cause analysis, identification “***of all the actions to prevent recurrence***,” and verification “***that the issue has in fact gone away or been reduced***,” respectively, as required by 21 CFR 820.100(a)(2), 820.100(a)(3), and 820.100(a)(4). For example:\u003C\u002Fp>\u003Cp>1. Your corrective and preventative action (CAPA) procedure is inadequate in that it does not define or document the requirement to verify or validate corrective actions prior to implementation to ensure they are effective. For CAPA 1175 opened on 11\u002F30\u002F23 for \u003Cstrong>(b)(4)\u003C\u002Fstrong> blades received with metal debris, leftover burrs, and residue corresponding to \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>), the corrective actions included (1) increasing clean time to \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes for your in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning machines; (2) verifying use of the custom \u003Cstrong>(b)(4)\u003C\u002Fstrong> fixture; and (3) utilizing additional inspectional tools with both magnification and lighting. However, you did not perform verification or validation activities prior to implementation of the corrective actions to ensure they would be able to remove residue.\u003C\u002Fp>\u003Cp>2. For CAPA 1175, you failed to adequately implement section 5.3 of your CAPA procedure because your investigation did not include an assessment on whether the residue, caused by improper placement of the devices in the in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines, may have affected other devices with similar geometries which also use the in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines to remove residue and metal shards.\u003C\u002Fp>\u003Cp>3. For CAPA 1166 opened on 7\u002F11\u002F22 to address “staining and contaminants on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>” on at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) you contract manufactured under 30 work orders between 1\u002F7\u002F19 to 8\u002F22\u002F22, you failed to implement sections 5.3, 5.4, and 5.5 of your CAPA procedure: (1) investigate the specific causes behind the different types of stains (light stain, glue\u002Ftransfer, oxidation, dark stain, and material transfer); (2) provide objective evidence that return material authorizations (RMAs) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines were monitored from 3\u002F10\u002F23 to 3\u002F17\u002F23 per the verification plan; and (3) prevent recurrence of this issue in that from 3\u002F17\u002F23 to 4\u002F1\u002F24, you received 7 additional customer complaints\u002Fexternal NCMs (3893; 3902; 3946; 3947; 3980; 3982; and 3984) for stains on at least 7 of the same part numbers (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) processed under 7 different work orders that were shipped after implementation of the corrective action on 3\u002F10\u002F23.\u003C\u002Fp>\u003Cp>B. Your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Eff. 6\u002F28\u002F22), which includes criteria for when corrective and preventive actions (CAPAs) should be initiated, is inadequate in that it does not define and document requirements for analyzing quality data (e.g., complaints, nonconformances, processes, returns, CAPAs, etc.) to identify existing and potential causes of nonconforming product, or other quality problems, using appropriate statistical methodology where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\u003Cp>1. Section 6.0 outlines the threshold for when a CAPA should be initiated for a nonconformance report. Threshold categories include Critical to Quality (Score: \u003Cstrong>(b)(4)\u003C\u002Fstrong>); Rejection % (Score: \u003Cstrong>(b)(4)\u003C\u002Fstrong>); Occurrence (Score \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and Detectability (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). A combined score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or above requires initiation of a CAPA. However, your “Detectability” rating does not associate lower ability to detect a nonconformity with a higher risk as a score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is defined as “Almost Certain” while a score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is defined as “Low to Almost Impossible.” Under this scoring system, recurring quality problems may not be detected because a CAPA would not be initiated for cases where detection was low to almost impossible.\u003C\u002Fp>\u003Cp>2. Section 5.8.3 states “***the QC Operations Manager***shall review nonconformance data***and determine if trends [for scrapped items, reworked product, nonconforming materials (NCMs)] or significant issue are identifiable and corrective action is warranted***” and that NCM\u002FCAPA meetings will be held periodically to discuss the status of open NCM\u002FCAPAs, trends, and NCM history. However, the procedure does not define and document how you are to analyze internal and external nonconformances as well as other quality data sources (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> data) to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology.\u003C\u002Fp>\u003Cp>3. Your nonconformance procedure does not define and document requirements to analyze nonconformances generated from a process that may encompass various part numbers in that your firm’s management stated you only trend nonconformance types by part number. During the inspection, analysis of nonconformances associated with stains between 1\u002F1\u002F20 to 4\u002F1\u002F24 by part number failed to detect a notable trend. When the same data set was analyzed across part numbers, there were 48 nonconformances associated with stains across \u003Cstrong>(b)(4)\u003C\u002Fstrong> unique part numbers.\u003C\u002Fp>\u003Cp>4. Your nonconformance procedure does not define and document the nonconformance types (e.g., Major, Manufacturing, GMP, Functional, Dimensional, Gauge etc.), used to categorize nonconformances, to ensure nonconforming product will be consistently assigned a NCM (nonconforming material) type to allow for accurate analysis of this data to identify existing and potential causes of nonconforming product, or other quality problems. For example, NCM # 3458 and NCM # 3469 represent nonconformances associated with devices failing no-go gauges. Employee \u003Cstrong>(b)(4)\u003C\u002Fstrong> categorized NCM # 3458 as “Dimensional” and the same employee characterized NCM # 3469 as “Guage.” These nonconformances referenced different work orders; however, they each contained identical descriptions, dispositions, and verifications which are specific to the same dimension and no-go gauge.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to CAPA 1175, you plan to investigate the feasibility of the process improvement determined from this CAPA on other product lines. However, there were no corrective actions identified to update your CAPA procedure to include verification or validation of corrective actions prior to implementation.\u003C\u002Fp>\u003Cp>With regards to CAPA 1166, you explain that staining occurred after product left your firm because you were unable to replicate some of the observed staining; you implemented a 100% visual inspection prior to packaging and shipment and plan to document the visual inspection records for the multiples \u003Cstrong>(b)(4)\u003C\u002Fstrong> orders verified from 3\u002F10\u002F23 to 3\u002F17\u002F23 as evidence; and you monitored RMAs requests across products lines for \u003Cstrong>(b)(4)\u003C\u002Fstrong> associated with staining, marks, and contamination from 3\u002F10\u002F23 to 3\u002F17\u002F23 as required by your verification plan. However, none of these conclusions, details, or activities were documented or referenced in your CAPA as part of the investigation, corrective action, and\u002For verification activities. Overall, there were no corrective actions identified to address the failure to include objective evidence of verification; incomplete documentation of the full investigation, identified corrective actions, and verification plan; and observed recurrence of the issue.\u003C\u002Fp>\u003Cp>With regards to data analysis, you state you intend to define a final internal nonconforming material (NCM) tracking and trending process within a procedure. However, there were no corrective actions identified to revise the detectability score to ensure that the lowest detectability level equates to the highest score \u003Cstrong>(b)(4)\u003C\u002Fstrong> not lowest score \u003Cstrong>(b)(4)\u003C\u002Fstrong> and retrospectively review NCMs, for a reasonable period of time, to update CAPA threshold scores to determine whether any CAPAs should have been initiated.\u003C\u002Fp>\u003Cp>With regards to categorization of nonconformances, you plan to review and update the existing NCM types listed within the system (as needed); define NCM types; and add instructions on how to correct NCM types after initial entry. However, there were no corrective actions identified to retrospectively review NCM types for accuracy, for a reasonable period of time, to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22) (nor any other procedure) is inadequate in that there is no requirement to identify, document, and evaluate the following internal nonconformances to determine the need for an investigation. For example:\u003C\u002Fp>\u003Cp>A. \u003Cu>Internal Nonconformances, found during manufacturing and inspections (excluding \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu> inspections\u003C\u002Fu> – Per your undocumented process, a supervisor logs parts that are out of specification (OOS) into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software application and informs your Quality Control (QC) Operations Manager, who in turn enters it on the “Internal NO NCM Issues” log and decides whether to open an official NCM report requiring an investigation per the nonconforming product procedure.\u003C\u002Fp>\u003Cp>B. \u003Cu>Internal nonconformances, only found during \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu> inspections conducted during manufacturing\u003C\u002Fu> – Per your undocumented process, your QC Operations Manager evaluates the part, approves the disposition of scrap on the inspection guide sheet (IGS), documents it on the “NCM Internal \u003Cstrong>(b)(4)\u003C\u002Fstrong> Scrap Log” and then discards the part along with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> report containing the OOS measurement. In turn, your operator enters the scrap on the IGS and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. There were no actions identified to define and document how internal nonconformances will be evaluated to determine the need for an investigation. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to establish and maintain procedures for acceptance activities, including inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 6.1.6.1(o) of your “Inspection Process” procedure (SOP-54; Rev. L; Effective: 3\u002F17\u002F23) which states the supervisor (or designate) “***must adhere to the Inspection Frequency as written. If the Inspection Frequency is at an AQL level, the Inspection Frequency is derived from DOC-03 PPI Sampling Plan***.” DOC-3 further references “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Acceptance Number Sampling Plan Fifth Edition” which requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling. For example:\u003C\u002Fp>\u003Cp>A. During in-process inspection of the small spacer intended for implantation during shoulder surgery (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your personnel only used your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to measure the critical diameter feature \u003Cstrong>(b)(4)\u003C\u002Fstrong> times (to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Per your inspection guide sheet (IGS) for this part, the feature was required to be measured \u003Cstrong>(b)(4)\u003C\u002Fstrong> times at \u003Cstrong>(b)(4)\u003C\u002Fstrong> since the inspection plan was specified to follow the Acceptable Quality Limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (AQL \u003Cstrong>(b)(4)\u003C\u002Fstrong>) defined in “PPI Sampling Plan” (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) for lot sizes of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> under the respective Work Orders (WO) 86995 and 99431, respectively. For WO # 86995, you received a complaint\u002Fexternal nonconformance (NCM # 3287\u002FCAPA 1122) which resulted in \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices being returned and scrapped due to diameters exceeding the specified limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> +\u002F- \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. On 5\u002F17\u002F24, our investigator observed employee \u003Cstrong>(b)(4)\u003C\u002Fstrong> operate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for machining of the metal locking date ring (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) under WO # 102106. Your operator explained that every \u003Cstrong>(b)(4)\u003C\u002Fstrong> piece is inspected using a caliper. However, the in-process router states that this operation requires a 100% inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to revise the IGS to include column headers and an explanation to record the data for the first setup piece, middle piece, and last piece; review and update the inspection process procedure with the above changes; and provide training on these requirements with an emphasis for operators to follow the specified \u003Cstrong>(b)(4)\u003C\u002Fstrong> frequency. However, there were no actions identified to determine to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to adequately establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).\u003C\u002Fstrong> Specifically:\u003C\u002Fp>\u003Cp>A. Your procedure to define and document the schedule for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowl and filter gauge pressure of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is inadequate. The “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” manual requires drainage and monitoring of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> volume on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis to prevent liquid from dripping on internal machine components. However, your firm only conducts and documents this maintenance \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning System Maintenance Log (Form-03). In addition, although the manual states that the filter gauge pressure should be checked \u003Cstrong>(b)(4)\u003C\u002Fstrong> and changed if it reaches \u003Cstrong>(b)(4)\u003C\u002Fstrong> PSI, there is no requirement to check the filter gauge pressure under the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” section of your maintenance log (or elsewhere).\u003C\u002Fp>\u003Cp>B. You do not define, document, and maintain schedules for the adjustment and maintenance of tooling to ensure manufacturing specifications are met. For example, on 4\u002F26\u002F24, our investigator observed an instance where your \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine was operating with a 0% tool life during the manufacturing of Work Order 101053-1. Per your firm’s management, tool changes may be considered when the machinist deems it necessary based on associated feature measurements, visual checks for a nonconformity on the surface finish of the part, or changes in the tool sound while engaged in the cut. In addition, the machinist may make an adjustment in the tool data page to compensate for the tool wear.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. As a part of the revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you plan to review the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” manual and compare it with the existing preventive maintenance form and update the frequency as needed, and if you determine that a frequency different from what the manual dictates is acceptable, a risk assessment will be performed and documented. You also state that the tooling observation is under review while you consider the best course of action. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>8. Failure to adequately establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, operators who conduct machining of raw materials, assembly, and finishing have not been trained on your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22). For example, review of 11 training records revealed \u003Cstrong>(b)(4)\u003C\u002Fstrong> operators who have not been trained in this procedure. These individuals perform in-process inspections and have the ability to reject and accept devices.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to update your nonconforming product procedure to include a section for all operators, finishers, and inspectors to state what should be done in the event nonconforming product is found during manufacturing and train all applicable employees to this updated procedure. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review and timelines for completion.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS Case # 697119 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeanne M. Phillips\n\nRecipient Title\n\nOwner and CEO\n\nPhillips Precision, Inc.\n\n7 Paul Kohner Pl\n\nElmwood Park, NJ 07407\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 697119\nDecember 9, 2024\nDear Ms. Jeanne M. Phillips:\nDuring an inspection of your firm located in Elmwood Park, NJ on April 22, 2024 through July 17, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures orthopedic implants and instruments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Ms. Shalyn Creighton, Quality Assurance and Regulatory Compliance Manager, dated August 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you either failed to adequately implement or define and document requirements for your “Master Validation Plan Process and Software Validation” procedure (SOP-34; Rev. M and O; Effective: 6\u002F13\u002F14 and 5\u002F9\u002F19) which governed process validations for the (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) and (b)(4) processes. For example:\nA. Cleaning validations conducted for the “(b)(4)” used to (b)(4) clean orthopedic implants and instruments, for which your firm functions as the final cleaner for (b)(4) out of (b)(4) top customers, do not provide adequate assurance that the process consistently produces product that meets specifications. For example:\n1. You failed to adequately implement sections 5.3.7 and 5.3.9.3 of your process validation procedure (SOP-34; Rev. M) which required you to challenge your cleaning process under the worst-case product and process conditions during the operational qualification (OQ) of your “(b)(4)” conducted under “Final (b)(4) Cleaning Operational Qualification (OQ) Protocol” (OQ_920-001; Rev. B; Approved 2\u002F5\u002F15), which includes the report. For example:\ni. Although your performance qualification (PQ) protocol required cytotoxicity, endotoxin, and particulate testing for the “(b)(4)” to demonstrate that cleanliness requirements were consistently met, you failed to conduct such testing during OQ which is defined in your procedure as “***documented verification that equipment performs in accordance with manufacturer’s specifications and process operating at [sic] the extremes of the equipment or process operating capabilities***.”\nii. You failed to adequately challenge the cleaning process under worst-case process parameters and product based on types and\u002For geometries, surface finishes, and processes conducted during OQ. For example, you did not challenge (b)(4) as all loads were run at (b)(4); system (b)(4) quality above (b)(4) microsiemens\u002F cm; clean time below (b)(4) minutes; and load weight above (b)(4) pounds. You also failed to define the worst-case setting for degassing time in the OQ protocol which your firm’s management stated is under (b)(4) minutes as well as document the degassing time during OQ.\nIn addition, you executed work orders during OQ without the (b)(4) manufacturing process, which your firm’s management identified during the inspection as a process that challenges your firm’s surface finishes and equipment process capabilities in (b)(4) out of (b)(4) work (WO #: 99343, 99284, 99336, and 98026-1) which were provided as worst case products.\nFurthermore, our investigator observed adhesive tape on the proximal femur left plasma implant (PF-2000L-02M; WO 102275) in the finishing department on 4\u002F26\u002F24. However, your OQ did not include challenges associated with the removal of adhesives and your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) does not establish cleaning specifications associated with this process.\niii. You failed to define or document the load configuration for work orders 65926 ((b)(4) devices), 64205 ((b)(4) devices), 63988 ((b)(4) devices), 65917 ((b)(4) devices), 65921 ((b)(4)75 devices), and 65791 ((b)(4) devices) in the OQ protocol and report in that your firm could not determine if devices were put in a single cleaning load or broken up into multiple (b)(4). In addition, you failed to challenge different loading configurations that your firm’s management stated are used during routine production such as the use of (b)(4) which is allowed in section 5.2.4.2.6 of your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) and (b)(4). On 4\u002F26\u002F24, our investigator observed the tibia stylus assembly instrument (Part # (b)(4); WO 101881) enclosed in a (b)(4) and the (b)(4) instrument (Part # (b)(4); WO 98151) placed on top of a (b)(4), neither of which were evaluated during OQ.\n2. You failed to adequately implement section 5.3.9.4 of process validation procedure (SOP-34; Rev. M) which required “***documented evidence that a process system performs as intended and that it demonstrates the capability to consistently meet appropriate specifications***” for the performance qualification (PQ) of your “(b)(4)” conducted under “Final (b)(4) Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report. For example:\ni. As specified in section 5.2.2 of your “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), you are to ensure that the system (b)(4) quality of the rinse tank is below (≤ (b)(4) microsiemens\u002Fcm) during normal operation of your (b)(4) cleaner. However, you failed to conduct PQ under normal operating conditions for system (b)(4) quality in that only (b)(4) out of (b)(4) runs were run at ≤ (b)(4) microsiemens\u002Fcm while the remaining cycles were run at (b)(4) and (b)(4) microsiemens\u002Fcm. In addition, you failed to define the optimal setting for degassing time in the PQ protocol as well as document the degassing time during execution of your PQ.\nii. You failed to utilize (b)(4) and (b)(4) which were sufficiently representative of manufactured devices. For example, WO # 99284 (Part # (b)(4)) includes surface finishes such as vibratory, deburring, and finishing and equipment processes such as (b)(4), assembly, machine, and (b)(4); however, these processes were not represented in the (b)(4) and (b)(4) utilized during your PQ and your firm did not document justification for the equivalency of those (b)(4) and (b)(4) through objective evidence.\n3. You failed to adequately implement section 5.1 of your process validation procedure (SOP-34; Rev. M) which requires a completed process failure modes and effects analysis (PFMEA) as a part of an approved validation plan and for which the definition under section 5.3.14 indicates that a PFMEA is used to “***assess quality risk levels to each step in a manufacturing process***” with a reference to your “Risk Management” procedure (SOP-35; Rev. K; Effective: 3\u002F9\u002F15) which outlines the criteria for severity scores on a scale of (b)(4) through (b)(4). For example, per section 10.4 of the “Final (b)(4) Cleaning Validation Plan” (VP_920_001; Rev. D; Effective: 3\u002F31\u002F15) for the “(b)(4)”, you utilized a PFMEA to assess quality risk levels that “***reflect[ed] the worst case process (for both clean and rinse) via processing***at maximum loading conditions (i.e. weight) for variable (b)(4) states @ (b)(4), (b)(4), and (b)(4)***.” However, you assigned a severity of (b)(4) ((b)(4)) out of (b)(4) for all but one of the failure modes for devices cleaned with your “Zenith” without determining if your firm was the final clean and if a severity score of 4 was appropriate. Your firm did not learn that it was the final clean for (b)(4) out of (b)(4) of your top customers until this information was requested during the inspection on 5\u002F2\u002F24. As of the close of the inspection, your firm had not evaluated the 8 other customers you have manufactured for since 2020 to determine if your firm is the final clean for them as well. For the 4 top customers for which your firm was the final cleaner, your firm manufactured and shipped (b)(4) implants and (b)(4) instruments for Customer (b)(4); (b)(4) implants and (b)(4) instruments for Customer (b)(4); (b)(4) implants and (b)(4) instruments for Customer (b)(4); and (b)(4) instruments for Customer (b)(4).\nB. You failed to adequately implement 5.3.8 of your process validation procedure (SOP-34; Rev. O) which requires “***documented evidence providing high degree of assurance that a process***will consistently perform as intended” in that:\n1. You have not conducted a process validation for additional post-production final cleaning processes listed in the “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), which allows for the use of (b)(4) and (b)(4), to provide adequate assurance that the process will consistently produce product that meet specifications. For example, on 4\u002F22\u002F24 and 4\u002F26\u002F24, our investigator observed your operators using (b)(4) and (b)(4) to wipe devices which had already been cleaned on the “(b)(4)”.\n2. The “Validation Plan for (b)(4)” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) only included devices composed of (b)(4) and (b)(4) stainless steel and did not include devices composed of titanium (which your firm’s management stated are also treated with (b)(4) during manufacturing) or documented justification for why validation of such devices was not necessary.\nC. You failed to adequately implement section 5.3.9.4 of your process validation procedure (SOP-34; Rev. M and O) which required “***documented evidence that a process system***demonstrates the capability to consistently meet appropriate specification***” and “***how\u002Fwhen samples will be taken, labeled, transported, and tested***” for the performance qualification (PQ) of your “(b)(4)”. For example:\n1. Your “Final (b)(4) Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report, for the “(b)(4)” did not utilize a sampling plan based on a valid statistical rationale for cytotoxicity, endotoxin, and particulate testing. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of (b)(4) unless otherwise specified, the number of (b)(4) tested per lot for cytotoxicity and endotoxin was (b)(4) and (b)(4), respectively and the number of (b)(4) units tested for cytotoxicity, endotoxin, and particulate was (b)(4), and (b)(4), respectively. An AQL of (b)(4) for a sample size of (b)(4) and (b)(4) units per lot would have required testing on (b)(4) samples per lot for each test.\n2. Your “Validation Plan for (b)(4)” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) did not utilize a sampling plan based on a valid statistical rationale. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of (b)(4) unless otherwise specified, cytotoxicity testing was only conducted on (b)(4) out of (b)(4) per lot and endotoxicity and particulate testing was conducted on (b)(4) per lot. An AQL of (b)(4) would have required a sufficient number of samples to be able to test a minimum of (b)(4) samples each for endotoxins, cytotoxicity, and particulates for a lot size between (b)(4) and (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to the OQ for the “(b)(4)”, you plan to update the (b)(4) cleaning procedure and perform a revalidation which will challenge: the minimum and maximum critical process parameters with worst-case product and process (b)(4); removal of any adhesives; load configurations; comingling; multiple (b)(4); and (b)(4). However, there was no confirmatory statement that you plan to conduct cytotoxicity, endotoxin, and particulate testing during OQ or rationale for why this would not be necessary and explanation provided for use of worst-case product and process (b)(4) instead of actual products during OQ.\nWith regards to PQ for the “(b)(4)”, you dispute that (b)(4) purity of the rinse tank was not conducted at nominal; however, the (b)(4) and (b)(4) cycle was not done under normal operating conditions. You plan to update the (b)(4) cleaning procedure and perform a revalidation to include notation of the degassing time and use of worst-case product (b)(4). However, there was no corrective action identified to run system (b)(4) purity under normal operating conditions (≤ (b)(4) microsiemens\u002Fcm) and define the optimal degassing time.\nWith regards to the PFMEA for the “(b)(4)”, you intend to review and update the existing PFMEA as needed; contact (b)(4) of the (b)(4) customers you still do business with to determine whether your firm is the final clean and request their risk assessment; and do the same for any new customers in the future. However, there was no corrective action identified to proceduralized these actions. Furthermore, it is not clear whether you plan to update the respective severity scores for the process failure modes of the “(b)(4)”, for customer devices for which you are determined to be the final clean, in order to establish adequate quality risk levels.\nWith regards to (b)(4), you plan to “amend” the (b)(4) validation to include devices composed of titanium. However, it is unclear what the difference is between an amendment and a revalidation.\nWith regards to process validation for additional post-production cleaning processes, you state that the use of (b)(4), and (medical grade) (b)(4) to wipe post-production and post-final-cleaning is done in accordance with customer requirements. However, no supporting evidence was provided and rationale for why post-production final cleaning processes would be needed if the final cleaning process is meant to assure that cleaning requirements can consistently be met.\nWith regards to sampling, you plan to update the process validation procedure and ensure that the revalidation of the “(b)(4)” and amendment of the (b)(4) validation will utilize a statistically valid sampling plan based on documented rationale.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n2. Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a).\nSpecifically, you failed to implement your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21). For example:\nA. You failed to implement section 5.2.4.2.5 which states “(b)(4).” For example, on 4\u002F26\u002F24, our investigator observed comingling of the large (b)(4) instrument (Part # (b)(4); WO 101395) and (b)(4) instrument (Part # (b)(4); WO 99014) in the same (b)(4) load.\nB. You failed to implement section 5.2.4.2.1 which states “Do not stack product.” For example, on 4\u002F26\u002F24, our investigator observed two instances where devices were stacked upon each other within a cleaning load: (b)(4) release instrument (Part # (b)(4); WO 98145) and (b)(4) instrument (Part # (b)(4); WO 98151), which appeared be stacked in 3 layers. In addition, the “(b)(4)\" manual specifically states that “(b)(4).”\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to perform a revalidation on the “(b)(4)” to include challenges such as comingling and load configurations during OQ and review and update the PFMEA and (b)(4) cleaning procedure, as applicable. However, you have not provided any timelines for completion of any of your corrective actions and there was no corrective action identified to address that your employees were not following procedures. Furthermore, it is not clear how a revalidation on the “(b)(4)” that challenges comingling will address the original purpose which was to (b)(4), as noted in your (b)(4) cleaning procedure. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). Specifically:\nA. You have not defined and documented procedures to monitor and control the following parameters for the validated (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) used to clean orthopedic implants and surgical instruments, for which your firm functions as the final cleaner for (b)(4) out of (b)(4) top customers:\n1. Weight of the Load (b)(4): There is no procedure to ensure that the load (b)(4) weight is below (b)(4) pounds, which was determined to be the limit during validation.\n2. Batch-to-Batch Temperature of the Cleaning Solution (i.e., Detergent) in the Clean and Rinse Tanks: There is no procedure to ensure that temperatures of the cleaning solution in the clean and rinse tanks between runs do not exceed the temperature limit of (b)(4)℉, which was determined to be the limit during validation.\n3. Concentration of the Cleaning Solution (i.e., Detergent): There is no procedure to ensure that the concentration of cleaning solution is monitored and controlled on a (b)(4) basis (with the use of a titration kit or other suitable means) to ensure adequate cleaning, which was specified during validation to be established per manufacturer’s instructions.\n4. Time for Degassing of Cleaning Solution (i.e., Detergent): There is no procedure to ensure that your “(b)(4)”, which operates at (b)(4)kHz, is degassed for (b)(4) to (b)(4) minutes before use for effective cavitation, which was specified during validation to be established per manufacturer’s instructions.\nB. You failed to implement sections 5.2.1.2 and 5.2.2.4 of your “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) which requires verification of the temperature of the cleaning solution (i.e., detergent) in the clean and rinse tanks to ensure it is in the validated range of (b)(4)℉ to (b)(4)℉ and documentation of the temperature on the “(b)(4) Cleaning System Daily Temperature Log” (Form-03_01; Rev. F; Effective: 5\u002F25\u002F19) during startup of your “(b)(4)”. Overall, review of the temperature log from January 2, 2023 and March 26, 2024 revealed that approximately (b)(4)% ((b)(4) out of (b)(4)) of the loads run on your “(b)(4)” were performed at out of specification temperatures. For example, your employees operated your (b)(4) cleaner at temperatures lower than the minimum specified limit of (b)(4)℉ on 2\u002F28\u002F23; 4\u002F6\u002F23; 4\u002F25\u002F23; 5\u002F19\u002F23; 5\u002F20\u002F23; 5\u002F22\u002F23; 5\u002F24\u002F23; and 7\u002F1\u002F23, implicating at least (b)(4) orthopedic devices ((b)(4) implants and (b)(4) surgical instruments).\nC. You have not established a procedure for the monitoring and control of temperature and time for (b)(4). Section 6.2 of your “(b)(4)” procedure (WI-920-005; Rev. F; Effective: 9\u002F6\u002F17) states that the “***(b)(4) is pre-heated***between (b)(4) and (b)(4) F for a minimum of (b)(4) prior to application.”\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to the inadequate monitoring and control of the above parameters, you plan to reevaluate monitoring and controls after revalidation of the “(b)(4)”; update the frequency as needed; and revise the (b)(4) cleaning procedure to establish the applicable batch-to-batch temperature for the tanks.\nWith regards to out of specification temperature recordings, you explain the temperatures would have increased as the morning went on such that only the first one or two runs of each day would have been affected; your employee may have misunderstood the process and either was not fully aware of the minimum temperature and\u002For what to do in the event the temperature was below the limit; and that because the minimum temperature proposed in the user manual is (b)(4)℉ and that the (b)(4) cleaning action only begins to deteriorate when temperatures go above certain limits (typically (b)(4)℉), the risk of impact to the parts cleaned on the specified days is low. However, there were temperatures noted above the validated temperature range of (b)(4)℉ on 8\u002F18\u002F23; 10\u002F10\u002F23; 1\u002F15\u002F24; 2\u002F1\u002F24; and 4\u002F1\u002F24. Additional temperatures below (b)(4)℉ were also noted on 8\u002F7\u002F23; 8\u002F12\u002F23; 8\u002F24\u002F23; and 11\u002F3\u002F23.\nYou also plan to update the (b)(4) cleaning procedure to include an explanation of what to do in the event the temperature is below the minimum temperature; train applicable employees as well as to the nonconforming product procedure to identify nonconformances regarding parts themselves; and update the PFMEA to include the risks associated with parts processed outside of the specified temperature limits. However, there were no corrective actions identified to (1) address that your employees were not following procedures to ensure that the startup temperatures were within specified limits and (2) update the (b)(4) cleaning procedure to specify how long employees should wait before measuring the temperature for verification before use of the (b)(4) cleaner.\nWith regards to the inadequate monitoring and control of parameters for (b)(4), you plan to review the (b)(4) validation and establish the applicable monitoring and control and amend the (b)(4) procedure to these said controls.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically:\nA. You either failed to define and document requirements in your Corrective\u002F Preventive Action Process” procedure (SOP-29, Rev. F, Effective: 10\u002F19\u002F18) or adequately implement sections 5.3, 5.4, and 5.5 which require a “***comprehensive and thorough***” root cause analysis, identification “***of all the actions to prevent recurrence***,” and verification “***that the issue has in fact gone away or been reduced***,” respectively, as required by 21 CFR 820.100(a)(2), 820.100(a)(3), and 820.100(a)(4). For example:\n1. Your corrective and preventative action (CAPA) procedure is inadequate in that it does not define or document the requirement to verify or validate corrective actions prior to implementation to ensure they are effective. For CAPA 1175 opened on 11\u002F30\u002F23 for (b)(4) blades received with metal debris, leftover burrs, and residue corresponding to (b)(4) devices (Part # (b)(4)), the corrective actions included (1) increasing clean time to (b)(4) minutes for your in-process (b)(4) cleaning machines; (2) verifying use of the custom (b)(4) fixture; and (3) utilizing additional inspectional tools with both magnification and lighting. However, you did not perform verification or validation activities prior to implementation of the corrective actions to ensure they would be able to remove residue.\n2. For CAPA 1175, you failed to adequately implement section 5.3 of your CAPA procedure because your investigation did not include an assessment on whether the residue, caused by improper placement of the devices in the in-process (b)(4) machines, may have affected other devices with similar geometries which also use the in-process (b)(4) machines to remove residue and metal shards.\n3. For CAPA 1166 opened on 7\u002F11\u002F22 to address “staining and contaminants on the (b)(4)” on at least (b)(4) devices (Part # (b)(4)) you contract manufactured under 30 work orders between 1\u002F7\u002F19 to 8\u002F22\u002F22, you failed to implement sections 5.3, 5.4, and 5.5 of your CAPA procedure: (1) investigate the specific causes behind the different types of stains (light stain, glue\u002Ftransfer, oxidation, dark stain, and material transfer); (2) provide objective evidence that return material authorizations (RMAs) for (b)(4) lines were monitored from 3\u002F10\u002F23 to 3\u002F17\u002F23 per the verification plan; and (3) prevent recurrence of this issue in that from 3\u002F17\u002F23 to 4\u002F1\u002F24, you received 7 additional customer complaints\u002Fexternal NCMs (3893; 3902; 3946; 3947; 3980; 3982; and 3984) for stains on at least 7 of the same part numbers ((b)(4)) processed under 7 different work orders that were shipped after implementation of the corrective action on 3\u002F10\u002F23.\nB. Your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Eff. 6\u002F28\u002F22), which includes criteria for when corrective and preventive actions (CAPAs) should be initiated, is inadequate in that it does not define and document requirements for analyzing quality data (e.g., complaints, nonconformances, processes, returns, CAPAs, etc.) to identify existing and potential causes of nonconforming product, or other quality problems, using appropriate statistical methodology where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example:\n1. Section 6.0 outlines the threshold for when a CAPA should be initiated for a nonconformance report. Threshold categories include Critical to Quality (Score: (b)(4)); Rejection % (Score: (b)(4)); Occurrence (Score (b)(4)); and Detectability ((b)(4)). A combined score of (b)(4) or above requires initiation of a CAPA. However, your “Detectability” rating does not associate lower ability to detect a nonconformity with a higher risk as a score of (b)(4) is defined as “Almost Certain” while a score of (b)(4) is defined as “Low to Almost Impossible.” Under this scoring system, recurring quality problems may not be detected because a CAPA would not be initiated for cases where detection was low to almost impossible.\n2. Section 5.8.3 states “***the QC Operations Manager***shall review nonconformance data***and determine if trends [for scrapped items, reworked product, nonconforming materials (NCMs)] or significant issue are identifiable and corrective action is warranted***” and that NCM\u002FCAPA meetings will be held periodically to discuss the status of open NCM\u002FCAPAs, trends, and NCM history. However, the procedure does not define and document how you are to analyze internal and external nonconformances as well as other quality data sources (e.g., (b)(4) data) to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology.\n3. Your nonconformance procedure does not define and document requirements to analyze nonconformances generated from a process that may encompass various part numbers in that your firm’s management stated you only trend nonconformance types by part number. During the inspection, analysis of nonconformances associated with stains between 1\u002F1\u002F20 to 4\u002F1\u002F24 by part number failed to detect a notable trend. When the same data set was analyzed across part numbers, there were 48 nonconformances associated with stains across (b)(4) unique part numbers.\n4. Your nonconformance procedure does not define and document the nonconformance types (e.g., Major, Manufacturing, GMP, Functional, Dimensional, Gauge etc.), used to categorize nonconformances, to ensure nonconforming product will be consistently assigned a NCM (nonconforming material) type to allow for accurate analysis of this data to identify existing and potential causes of nonconforming product, or other quality problems. For example, NCM # 3458 and NCM # 3469 represent nonconformances associated with devices failing no-go gauges. Employee (b)(4) categorized NCM # 3458 as “Dimensional” and the same employee characterized NCM # 3469 as “Guage.” These nonconformances referenced different work orders; however, they each contained identical descriptions, dispositions, and verifications which are specific to the same dimension and no-go gauge.\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to CAPA 1175, you plan to investigate the feasibility of the process improvement determined from this CAPA on other product lines. However, there were no corrective actions identified to update your CAPA procedure to include verification or validation of corrective actions prior to implementation.\nWith regards to CAPA 1166, you explain that staining occurred after product left your firm because you were unable to replicate some of the observed staining; you implemented a 100% visual inspection prior to packaging and shipment and plan to document the visual inspection records for the multiples (b)(4) orders verified from 3\u002F10\u002F23 to 3\u002F17\u002F23 as evidence; and you monitored RMAs requests across products lines for (b)(4) associated with staining, marks, and contamination from 3\u002F10\u002F23 to 3\u002F17\u002F23 as required by your verification plan. However, none of these conclusions, details, or activities were documented or referenced in your CAPA as part of the investigation, corrective action, and\u002For verification activities. Overall, there were no corrective actions identified to address the failure to include objective evidence of verification; incomplete documentation of the full investigation, identified corrective actions, and verification plan; and observed recurrence of the issue.\nWith regards to data analysis, you state you intend to define a final internal nonconforming material (NCM) tracking and trending process within a procedure. However, there were no corrective actions identified to revise the detectability score to ensure that the lowest detectability level equates to the highest score (b)(4) not lowest score (b)(4) and retrospectively review NCMs, for a reasonable period of time, to update CAPA threshold scores to determine whether any CAPAs should have been initiated.\nWith regards to categorization of nonconformances, you plan to review and update the existing NCM types listed within the system (as needed); define NCM types; and add instructions on how to correct NCM types after initial entry. However, there were no corrective actions identified to retrospectively review NCM types for accuracy, for a reasonable period of time, to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n5. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\nSpecifically, your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22) (nor any other procedure) is inadequate in that there is no requirement to identify, document, and evaluate the following internal nonconformances to determine the need for an investigation. For example:\nA. Internal Nonconformances, found during manufacturing and inspections (excluding (b)(4) inspections – Per your undocumented process, a supervisor logs parts that are out of specification (OOS) into the (b)(4) software application and informs your Quality Control (QC) Operations Manager, who in turn enters it on the “Internal NO NCM Issues” log and decides whether to open an official NCM report requiring an investigation per the nonconforming product procedure.\nB. Internal nonconformances, only found during (b)(4) inspections conducted during manufacturing – Per your undocumented process, your QC Operations Manager evaluates the part, approves the disposition of scrap on the inspection guide sheet (IGS), documents it on the “NCM Internal (b)(4) Scrap Log” and then discards the part along with the (b)(4) report containing the OOS measurement. In turn, your operator enters the scrap on the IGS and (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate. There were no actions identified to define and document how internal nonconformances will be evaluated to determine the need for an investigation. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n6. Failure to establish and maintain procedures for acceptance activities, including inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\nSpecifically, you failed to implement section 6.1.6.1(o) of your “Inspection Process” procedure (SOP-54; Rev. L; Effective: 3\u002F17\u002F23) which states the supervisor (or designate) “***must adhere to the Inspection Frequency as written. If the Inspection Frequency is at an AQL level, the Inspection Frequency is derived from DOC-03 PPI Sampling Plan***.” DOC-3 further references “(b)(4) Acceptance Number Sampling Plan Fifth Edition” which requires (b)(4) sampling. For example:\nA. During in-process inspection of the small spacer intended for implantation during shoulder surgery (Part # (b)(4)), your personnel only used your (b)(4) to measure the critical diameter feature (b)(4) times (to include (b)(4)). Per your inspection guide sheet (IGS) for this part, the feature was required to be measured (b)(4) times at (b)(4) since the inspection plan was specified to follow the Acceptable Quality Limit of (b)(4) (AQL (b)(4)) defined in “PPI Sampling Plan” (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) for lot sizes of (b)(4) and (b)(4) under the respective Work Orders (WO) 86995 and 99431, respectively. For WO # 86995, you received a complaint\u002Fexternal nonconformance (NCM # 3287\u002FCAPA 1122) which resulted in (b)(4) devices being returned and scrapped due to diameters exceeding the specified limit of (b)(4) +\u002F- (b)(4).\nB. On 5\u002F17\u002F24, our investigator observed employee (b)(4) operate the (b)(4) for machining of the metal locking date ring (Part # (b)(4)) under WO # 102106. Your operator explained that every (b)(4) piece is inspected using a caliper. However, the in-process router states that this operation requires a 100% inspection.\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to revise the IGS to include column headers and an explanation to record the data for the first setup piece, middle piece, and last piece; review and update the inspection process procedure with the above changes; and provide training on these requirements with an emphasis for operators to follow the specified (b)(4) frequency. However, there were no actions identified to determine to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n7. Failure to adequately establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1). Specifically:\nA. Your procedure to define and document the schedule for the (b)(4) bowl and filter gauge pressure of the (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) is inadequate. The “(b)(4)” manual requires drainage and monitoring of the (b)(4) volume on a (b)(4) basis to prevent liquid from dripping on internal machine components. However, your firm only conducts and documents this maintenance (b)(4) on the (b)(4) Cleaning System Maintenance Log (Form-03). In addition, although the manual states that the filter gauge pressure should be checked (b)(4) and changed if it reaches (b)(4) PSI, there is no requirement to check the filter gauge pressure under the “(b)(4)” section of your maintenance log (or elsewhere).\nB. You do not define, document, and maintain schedules for the adjustment and maintenance of tooling to ensure manufacturing specifications are met. For example, on 4\u002F26\u002F24, our investigator observed an instance where your (b)(4) machine was operating with a 0% tool life during the manufacturing of Work Order 101053-1. Per your firm’s management, tool changes may be considered when the machinist deems it necessary based on associated feature measurements, visual checks for a nonconformity on the surface finish of the part, or changes in the tool sound while engaged in the cut. In addition, the machinist may make an adjustment in the tool data page to compensate for the tool wear.\nWe reviewed your firm’s response and conclude that it is not adequate. As a part of the revalidation of the “(b)(4)”, you plan to review the “(b)(4)” manual and compare it with the existing preventive maintenance form and update the frequency as needed, and if you determine that a frequency different from what the manual dictates is acceptable, a risk assessment will be performed and documented. You also state that the tooling observation is under review while you consider the best course of action. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n8. Failure to adequately establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\nSpecifically, operators who conduct machining of raw materials, assembly, and finishing have not been trained on your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22). For example, review of 11 training records revealed (b)(4) operators who have not been trained in this procedure. These individuals perform in-process inspections and have the ability to reject and accept devices.\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to update your nonconforming product procedure to include a section for all operators, finishers, and inspectors to state what should be done in the event nonconforming product is found during manufacturing and train all applicable employees to this updated procedure. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review and timelines for completion.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS Case # 697119 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Phillips Precision, Inc.","phillips-precision-inc-697119-12092024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphillips-precision-inc-697119-12092024","2026-10-26T08:09:41.686932+00:00","Warning Letter","Issued","2025-01-14","697119","Medical Devices","Jeanne M. Phillips","2026-08-19T17:04:56.275+00:00","VIA Electronic Mail","2024-12-09",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},1862,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:20:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-05T04:00:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbyd-precision-manufacture-co-ltd-666250-09052023\">BYD Precision Manufacture Co., Ltd\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liu Xiaoling\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BYD Precision Manufacture Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Baolong Industrial, No. 3001 Baohe Road; Longgangjiedao\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Longgang Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>518116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 5, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Liu Xiaoling:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Shenzhen, Guangdong, China on May 22, 2023 through May 26, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures BYD Surgical Mask Model FE2111, BYD Surgical Mask Model FE2311B, and BYD N95 Respirator Model DE2322. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Shen Haigen, R&amp;D Engineer and Management Representative dated June 12, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm has not established procedures for design controls and was unable to provide records demonstrating conformance with design input, design output, design review, design verification, design validation, design transfer, design changes, and design history file for the surgical N95 respirators (Model DE2322) and surgical masks (Model FE2311 and Model FE2311B).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm did not provide procedures for design controls for surgical N95 respirator model DE2322 or surgical mask models FE2311 and 2311B. Your firm indicated that it had a “design control program file” approved December 30, 2019 but only provided design history file for surgical N95 respirator model DE2322.\u003C\u002Fp>\n\n\u003Cp>2. Failure to validate with a high degree of assurance and approve according to established procedures, processes where the results cannot be fully verified by subsequent inspections and tests. Failure to document validation activities and results, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Process Validation records were requested for the following processes that are used for manufacturing surgical N95 respirators and surgical masks: \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated elastic cutting machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated elastic-stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated metal nose piece attachment machines,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> - semi-automated stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> individual mask package sealer machines, and elastic band pull test. However, your firm was unable to provide records demonstrating where the results of a process cannot be fully verified by subsequent inspection and test, the process is validated with a high degree of assurance and approved according to established procedures.\u003C\u002Fli>\n\t\u003Cli>Your firm provided IQ\u002FOQ\u002FPQ reports for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> semi-automated face mask production machines used for manufacturing surgical N95 respirators and surgical masks; however, your firm was unable to provide a rationale for the sample size used during testing. Additionally, the validation reports were not dated and signed by the individual approving the validation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm provided validation documents for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (equipment number: 40002059), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (40001993), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (40001169), belt cutting machine (40002176), \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>machine (40001971), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine processes (40001984). However, the equipment numbers in the validation documents do not match the equipment numbers of those used in the manufacturing process. In addition, validation documents were not provided for all pieces of manufacturing equipment where there are multiple units. Your firm also did not propose a retrospective review to determine which pieces of manufacturing equipment needed validation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to maintain Device Master Records (DMR’s), as required by 21 CFR 820.181.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Device Master Records (DMRs) for N95 respirator mask or the single-use surgical mask were requested; however, your firm was unable to produce these records for review. Your firm’s Quality Manager stated that the DMR for N95 respirator mask or the single use surgical mask will need to be prepared.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm provided a DMR for surgical N95 respirator model DE2326. However, your firm stated during the inspection that only model DE2322 was manufactured and shipped for the U.S. market. A DMR was not provided for surgical N95 respirator model DE2322 or any of the surgical masks. In addition, your firm did not indicate how it would handle products that were released without a DMR and whether there would be training on new procedures.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish procedures for receiving, reviewing and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm‘s Customer Feedback Procedure, No. MSP-20-D23-009, Rev. A\u002F0, dated 2020-March-28, does not include a process for determining whether a complaint represents an event which is required to be reported to FDA under part 803, Medical Device Reporting.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You stated that you have modified the customer feedback procedure to “\u003Cem>improve the missing content of the program file\u003C\u002Fem>.” However, no documentation was provided for FDA to evaluate. In addition, you did not indicate whether there will be a retrospective review to determine if any old complaints needed to be reported as MDRs and whether there will be training on the new procedure.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, your firm identified a partially English-translated version of the document titled “Procedure for the Control of Advisory Notifications and Adverse Event Reporting for Medical Device Products”, MSP-20-D23-006, Ver. A\u002F1, dated 5\u002F11\u002F2020, as its MDR procedure. After reviewing the document, we conclude that it does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17. Specifically,\u003C\u002Fp>\n\n\u003Cp>1. The document does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>\nb. The document does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>2. The document does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\u003C\u002Fp>\n\n\u003Cp>a. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nb. The document, as written, does not specify who makes the decision for reporting events to FDA.\u003C\u002Fp>\n\n\u003Cp>3. The document does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the document does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. The circumstances under which your firm must submit initial 30 days, supplement or follow-up, 5 day report and the requirements for such reports.\u003Cbr>\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\u003Cbr>\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fp>\n\n\u003Cp>4. The document does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003C\u002Fp>\n\n\u003Cp>a. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>\nb. Information that was evaluated to determine if an event was reportable.\u003Cbr>\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>Additionally, based on our records, as of July 13, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. You noted that you are working with your U.S. subsidiary to develop and implement an MDR reporting process. However, there is no procedure available for the FDA to assess its adequacy.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 666250 when replying. If you have any questions about the contents of this letter, please contact: Bifeng Qian, M.D., Ph.D. at 301-796-2261.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nBinita S. Ashar, M.D., M.B.A., F.A.C.S.\u003Cbr>\nDirector\u003Cbr>\nOHT4: Office of Surgical and Infection Control\u003Cbr>\nDevices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nLisa Van\u003Cbr>\nNova Clinical Solutions\u003Cbr>\n4455 Eastgate Mall, Suite 200\u003Cbr>\nSan Diego, CA 92121\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nLiu Xiaoling\n\nRecipient Title\n\nGeneral Manager\n\nBYD Precision Manufacture Co., Ltd\n\nBaolong Industrial, No. 3001 Baohe Road; Longgangjiedao\n\nLonggang Qu\n\nShenzhen Shi\n\nGuangdong Sheng, 518116\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 5, 2023\n\nDear Liu Xiaoling:\n\nDuring an inspection of your firm located in Shenzhen, Guangdong, China on May 22, 2023 through May 26, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures BYD Surgical Mask Model FE2111, BYD Surgical Mask Model FE2311B, and BYD N95 Respirator Model DE2322. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Shen Haigen, R&D Engineer and Management Representative dated June 12, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30.\n\nFor example:\n\nYour firm has not established procedures for design controls and was unable to provide records demonstrating conformance with design input, design output, design review, design verification, design validation, design transfer, design changes, and design history file for the surgical N95 respirators (Model DE2322) and surgical masks (Model FE2311 and Model FE2311B).\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm did not provide procedures for design controls for surgical N95 respirator model DE2322 or surgical mask models FE2311 and 2311B. Your firm indicated that it had a “design control program file” approved December 30, 2019 but only provided design history file for surgical N95 respirator model DE2322.\n\n2. Failure to validate with a high degree of assurance and approve according to established procedures, processes where the results cannot be fully verified by subsequent inspections and tests. Failure to document validation activities and results, as required by 21 CFR 820.75(a).\n\nFor example:\n\nProcess Validation records were requested for the following processes that are used for manufacturing surgical N95 respirators and surgical masks: (b)(4) - automated elastic cutting machines, (b)(4) - automated elastic-stapler machines, (b)(4) - automated stapler machines, (b)(4) - automated metal nose piece attachment machines, (b)(4) - semi-automated stapler machines, (b)(4) individual mask package sealer machines, and elastic band pull test. However, your firm was unable to provide records demonstrating where the results of a process cannot be fully verified by subsequent inspection and test, the process is validated with a high degree of assurance and approved according to established procedures.\n\nYour firm provided IQ\u002FOQ\u002FPQ reports for the (b)(4) semi-automated face mask production machines used for manufacturing surgical N95 respirators and surgical masks; however, your firm was unable to provide a rationale for the sample size used during testing. Additionally, the validation reports were not dated and signed by the individual approving the validation.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm provided validation documents for the (b)(4) machine (equipment number: 40002059), (b)(4) machine (40001993), (b)(4) machine (40001169), belt cutting machine (40002176), (b)(4) machine (40001971), and (b)(4) machine processes (40001984). However, the equipment numbers in the validation documents do not match the equipment numbers of those used in the manufacturing process. In addition, validation documents were not provided for all pieces of manufacturing equipment where there are multiple units. Your firm also did not propose a retrospective review to determine which pieces of manufacturing equipment needed validation.\n\n3. Failure to maintain Device Master Records (DMR’s), as required by 21 CFR 820.181.\n\nFor example:\n\nDevice Master Records (DMRs) for N95 respirator mask or the single-use surgical mask were requested; however, your firm was unable to produce these records for review. Your firm’s Quality Manager stated that the DMR for N95 respirator mask or the single use surgical mask will need to be prepared.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm provided a DMR for surgical N95 respirator model DE2326. However, your firm stated during the inspection that only model DE2322 was manufactured and shipped for the U.S. market. A DMR was not provided for surgical N95 respirator model DE2322 or any of the surgical masks. In addition, your firm did not indicate how it would handle products that were released without a DMR and whether there would be training on new procedures.\n\n4. Failure to establish procedures for receiving, reviewing and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\n\nFor example:\n\nYour firm‘s Customer Feedback Procedure, No. MSP-20-D23-009, Rev. A\u002F0, dated 2020-March-28, does not include a process for determining whether a complaint represents an event which is required to be reported to FDA under part 803, Medical Device Reporting.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You stated that you have modified the customer feedback procedure to “improve the missing content of the program file.” However, no documentation was provided for FDA to evaluate. In addition, you did not indicate whether there will be a retrospective review to determine if any old complaints needed to be reported as MDRs and whether there will be training on the new procedure.\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nFor example, during the inspection, your firm identified a partially English-translated version of the document titled “Procedure for the Control of Advisory Notifications and Adverse Event Reporting for Medical Device Products”, MSP-20-D23-006, Ver. A\u002F1, dated 5\u002F11\u002F2020, as its MDR procedure. After reviewing the document, we conclude that it does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17. Specifically,\n\n1. The document does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\na. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb. The document does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\n2. The document does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\n\na. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. The document, as written, does not specify who makes the decision for reporting events to FDA.\n\n3. The document does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the document does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. The circumstances under which your firm must submit initial 30 days, supplement or follow-up, 5 day report and the requirements for such reports.\n\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\n\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n\n4. The document does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Information that was evaluated to determine if an event was reportable.\n\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nAdditionally, based on our records, as of July 13, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports.\n\nThe adequacy of your firm’s response cannot be determined at this time. You noted that you are working with your U.S. subsidiary to develop and implement an MDR reporting process. However, there is no procedure available for the FDA to assess its adequacy.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 666250 when replying. If you have any questions about the contents of this letter, please contact: Bifeng Qian, M.D., Ph.D. at 301-796-2261.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, M.D., M.B.A., F.A.C.S.\n\nDirector\n\nOHT4: Office of Surgical and Infection Control\n\nDevices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nLisa Van\n\nNova Clinical Solutions\n\n4455 Eastgate Mall, Suite 200\n\nSan Diego, CA 92121","BYD Precision Manufacture Co., Ltd","byd-precision-manufacture-co-ltd-666250-09052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbyd-precision-manufacture-co-ltd-666250-09052023","2026-10-26T08:08:09.787753+00:00","2023-09-12","666250","Liu Xiaoling","2026-08-20T00:41:41.972+00:00","2023-09-05",{"id":51,"raw":52,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":56,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},3549,[53,54,55,56,57,13,13,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-05T05:00:00Z\">02\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprecision-analitica-integral-sa-de-cv-609784-02052021\">Precision Analitica Integral S.A. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated\u003Cbr \u002F>\r\n","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Alan Williams\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Precision Analitica Integral S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Calle De Minas 501 Bodega 21\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Col. Arvide\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alvaro Obregon\u003C\u002Fspan>, \u003Cspan>CDMX\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-25\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 5, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Williams:\u003C\u002Fp>\n\n\u003Cp>Your firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer) labeled as CleanCare nogerm ADVANCED HAND SANITIZER. This drug product was labeled as manufactured at your facility, Precision Analitica Integral, FEI 3016855928, at Calle Minas 501 Bodega 21-22, Col. Lomas de Becerra Alc. Alcaro Obregon, Ciudad de Mexico, Mexico. Following an offer for import of this drug product into the United States, CleanCare nogerm ADVANCED HAND SANITIZER was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of a batch of this product detained at the border demonstrate that the CleanCare nogerm ADVANCED HAND SANITIZER drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the “Act”), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, CleanCare nogerm ADVANCED HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee). Introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CleanCare nogerm ADVANCED HAND SANITIZER, a drug product labeled as manufactured at your facility, is labeled to contain 75% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the product contained an average of 40% ethanol v\u002Fv and an average of 28% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On August 6, 2020, FDA held a teleconference with you and ESPMEX, LLC, your registered U.S. agent\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On August 7, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug product at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>As of the date of this letter, you have yet to initiate a recall on hand sanitizer products manufactured by your firm and distributed to the United States. However, FDA is still concerned regarding the quality of your hand sanitizer products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cp>• In a letter a respresentative of your U.S. Agent, ESPMEX, LLC, sent to FDA on July 21, 2020, ESPMEX, LLC provided the results of its investigation into how your hand sanitizer was contaminated with methanol. However, this investigation failed to provide a justification for why your firm failed to perform raw material (ethyl alcohol) or finished product testing for the CleanCare nogerm ADVANCED HAND SANITIZER imported to the U.S. Provide an updated, detailed investigation into your failure to perform raw material or finished product testing on your drug products.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• In August 2020, you provided copies of batch records for certain batches of hand sanitizers distributed to the U.S. Provide copies of the complete batch records for all batches distributed to the U.S.\u003Cbr>\n• During the August 6th teleconference with the Agency, you stated that your current supplier was adequate. However, on June 17, 2020 your U.S. Agent, ESPMEX, LLC, had indicated that your supplier may have been involved in contaminated material at another facility. In a communication on August 14, 2020, your counsel later stated that your U.S. Agent was initially incorrect. FDA remains concerned regarding your supplier qualification program. Provide details regarding your supplier qualification program and how it is compliant with human drug CGMP.\u003C\u002Fp>\n\n\u003Cp>The substitution and contamination with methanol in drug products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CleanCare nogerm ADVANCED HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended as a consumer antiseptic hand rub.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the CleanCare nogerm ADVANCED HAND SANITIZER product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Purpose\u003C\u002Fstrong> Antimicrobial . . . \u003Cstrong>Uses\u003C\u002Fstrong>: Hand Sanitizer to help reduce bacteria on skin that could cause diseases . . . . \u003Cstrong>Directions\u003C\u002Fstrong>: Place enough product in the palm of your hands to thoroughly cover your hands. Rub hands together briskly until product is completely absorbed and hands are dry.”\u003Cbr>\n\u003Cbr>\nThis hand sanitizer product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this hand sanitizer product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your CleanCare nogerm ADVANCED HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016). Over the course of these rulemakings, benzalkonium chloride, ethyl alcohol, and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, CleanCare nogerm ADVANCED HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act, for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, CleanCare nogerm ADVANCED HAND SANITIZER purportedly contains the active ingredient ethyl alcohol (ethanol) 75%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrate that CleanCare nogerm ADVANCED HAND SANITIZER contains a concentration of ethanol that is far less than the 75% declared on the label. Such a product does not conform with the TFM and other applicable requirements,\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> nor is it consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses of a batch of this product detained at the border also revealed that a sample of CleanCare nogerm ADVANCED HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is it included in the formulations described in FDA’s \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> \u003Cem>Guidance for Industry\u003C\u002Fem>. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that an OTC drug product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, CleanCare nogerm ADVANCED HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, CleanCare nogerm ADVANCED HAND SANITIZER is labeled to contain ethyl alcohol 75%. However, FDA laboratory analysis of a batch of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is far less than what is stated on the product label and instead contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the concentration of active ingredient ethyl alcohol (ethanol) and the failure of the product label to disclose the presence of methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this product to list methyl alcohol (methanol) as an ingredient on its label causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A). Furthermore, this product is misbranded under section 502(x) of the FD&amp;C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because CleanCare nogerm ADVANCED HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products listed as manufactured by your firm on Import Alert 66-78 on August 13, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016855928 and ATTN:CDR Frank Verni.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered US Agent\u003Cbr>\nErnesto Casillas, Director\u003Cbr>\nSamuel Casillas, Director ESPMEX, LLC\u003Cbr>\n3923 Purple Plum Ct\u003Cbr>\nLas Vegas, NV 89147-8078\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nOutside Counsel\u003Cbr>\nMr. Benjamin L. England, Esq.\u003Cbr>\nFounding Member\u003Cbr>\nBenjamin L. England &amp; Associates\u003Cbr>\n810 Landmark Drive, Suite 126\u003Cbr>\nGlen Burnie, MD 21061\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under section 510(i)(1) of the FD&amp;C Act, 21 U.S.C. 360(i)(1), you are required to submit registration information annually by electronic means for each foreign establishment you own or operate, engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States, and include the name of the United States Agent. As a drug manufacturer, it is your responsibility to ensure complete and accurate registration information.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the presence of methanol in your hand sanitizer product, a review of your drug product labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because CleanCare nogerm ADVANCED HAND SANITIZER is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Alan Williams\n\nRecipient Title\n\nCEO\n\nPrecision Analitica Integral S.A. de C.V.\n\nCalle De Minas 501 Bodega 21\n\nCol. Arvide\n\nAlvaro Obregon, CDMX\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-25\n\nFebruary 5, 2021\n\nDear Mr. Williams:\n\nYour firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer) labeled as CleanCare nogerm ADVANCED HAND SANITIZER. This drug product was labeled as manufactured at your facility, Precision Analitica Integral, FEI 3016855928, at Calle Minas 501 Bodega 21-22, Col. Lomas de Becerra Alc. Alcaro Obregon, Ciudad de Mexico, Mexico. Following an offer for import of this drug product into the United States, CleanCare nogerm ADVANCED HAND SANITIZER was detained and refused admission at the border.\n\nThe results of FDA laboratory testing of a batch of this product detained at the border demonstrate that the CleanCare nogerm ADVANCED HAND SANITIZER drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the “Act”), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, CleanCare nogerm ADVANCED HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee). Introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nCleanCare nogerm ADVANCED HAND SANITIZER, a drug product labeled as manufactured at your facility, is labeled to contain 75% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the product contained an average of 40% ethanol v\u002Fv and an average of 28% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nOn August 6, 2020, FDA held a teleconference with you and ESPMEX, LLC, your registered U.S. agent1. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On August 7, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug product at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nAs of the date of this letter, you have yet to initiate a recall on hand sanitizer products manufactured by your firm and distributed to the United States. However, FDA is still concerned regarding the quality of your hand sanitizer products.\n\nIn response to this letter provide the following:\n\n• In a letter a respresentative of your U.S. Agent, ESPMEX, LLC, sent to FDA on July 21, 2020, ESPMEX, LLC provided the results of its investigation into how your hand sanitizer was contaminated with methanol. However, this investigation failed to provide a justification for why your firm failed to perform raw material (ethyl alcohol) or finished product testing for the CleanCare nogerm ADVANCED HAND SANITIZER imported to the U.S. Provide an updated, detailed investigation into your failure to perform raw material or finished product testing on your drug products.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• In August 2020, you provided copies of batch records for certain batches of hand sanitizers distributed to the U.S. Provide copies of the complete batch records for all batches distributed to the U.S.\n\n• During the August 6th teleconference with the Agency, you stated that your current supplier was adequate. However, on June 17, 2020 your U.S. Agent, ESPMEX, LLC, had indicated that your supplier may have been involved in contaminated material at another facility. In a communication on August 14, 2020, your counsel later stated that your U.S. Agent was initially incorrect. FDA remains concerned regarding your supplier qualification program. Provide details regarding your supplier qualification program and how it is compliant with human drug CGMP.\n\nThe substitution and contamination with methanol in drug products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nCleanCare nogerm ADVANCED HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended as a consumer antiseptic hand rub.\n\nExamples of claims observed on the CleanCare nogerm ADVANCED HAND SANITIZER product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\nDrug Facts . . . Purpose Antimicrobial . . . Uses: Hand Sanitizer to help reduce bacteria on skin that could cause diseases . . . . Directions: Place enough product in the palm of your hands to thoroughly cover your hands. Rub hands together briskly until product is completely absorbed and hands are dry.”\n\nThis hand sanitizer product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this hand sanitizer product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your CleanCare nogerm ADVANCED HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016). Over the course of these rulemakings, benzalkonium chloride, ethyl alcohol, and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, CleanCare nogerm ADVANCED HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act, for marketing without an approved application under section 505.\n\nAccording to the product label, CleanCare nogerm ADVANCED HAND SANITIZER purportedly contains the active ingredient ethyl alcohol (ethanol) 75%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrate that CleanCare nogerm ADVANCED HAND SANITIZER contains a concentration of ethanol that is far less than the 75% declared on the label. Such a product does not conform with the TFM and other applicable requirements,3 nor is it consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.4\n\nFDA laboratory analyses of a batch of this product detained at the border also revealed that a sample of CleanCare nogerm ADVANCED HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is it included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that an OTC drug product’s inactive ingredients be safe and suitable.5\n\nAdditionally, this methanol-containing drug product, CleanCare nogerm ADVANCED HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, CleanCare nogerm ADVANCED HAND SANITIZER is labeled to contain ethyl alcohol 75%. However, FDA laboratory analysis of a batch of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is far less than what is stated on the product label and instead contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the concentration of active ingredient ethyl alcohol (ethanol) and the failure of the product label to disclose the presence of methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this product to list methyl alcohol (methanol) as an ingredient on its label causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A). Furthermore, this product is misbranded under section 502(x) of the FD&C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because CleanCare nogerm ADVANCED HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products listed as manufactured by your firm on Import Alert 66-78 on August 13, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\n\nIdentify your response with FEI 3016855928 and ATTN:CDR Frank Verni.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered US Agent\n\nErnesto Casillas, Director\n\nSamuel Casillas, Director ESPMEX, LLC\n\n3923 Purple Plum Ct\n\nLas Vegas, NV 89147-8078\n\nCC:\n\nOutside Counsel\n\nMr. Benjamin L. England, Esq.\n\nFounding Member\n\nBenjamin L. England & Associates\n\n810 Landmark Drive, Suite 126\n\nGlen Burnie, MD 21061\n\n___________________________\n\n1 Under section 510(i)(1) of the FD&C Act, 21 U.S.C. 360(i)(1), you are required to submit registration information annually by electronic means for each foreign establishment you own or operate, engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is imported or offered for import into the United States, and include the name of the United States Agent. As a drug manufacturer, it is your responsibility to ensure complete and accurate registration information.\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the presence of methanol in your hand sanitizer product, a review of your drug product labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n4 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because CleanCare nogerm ADVANCED HAND SANITIZER is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n5 An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Precision Analitica Integral S.A. de C.V.","precision-analitica-integral-sa-de-cv-609784-02052021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprecision-analitica-integral-sa-de-cv-609784-02052021","2026-10-26T08:09:43.352421+00:00","2021-02-09","609784","Drugs","Mr. Alan Williams","2026-08-20T03:24:33.679+00:00","VIA UPS","2021-02-05",3,{"510k":75,"classification":76,"enforcement":77,"event":78,"event_backfill":79,"pma":80,"warning_letter":81},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-22T04:00:36.543+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]